Using smart sensors to ensure vaccine safety

Using smart sensors to ensure vaccine safety
Percentage of change in chest-patch indicators compared to their levels observed on the day prior to vaccination. Percentage of change in respiratory, cardiovascular, and physiological indicators recorded by the chest-patch sensor compared to their levels observed on the day prior vaccination: a skin temperature, b heart rate, c cardiac output, d systemic vascular resistance, e systolic blood pressure, f diastolic blood pressure, g respiratory rate, and h oxygen saturation. Mean values are depicted as solid lines, 90% confidence intervals are presented as shaded regions, and horizontal dashed lines represent no change compared to the levels observed on the day prior to vaccination. The analysis is based on n=160n=160 participants. Credit: Communications Medicine (2022). DOI: 10.1038/s43856-022-00090-y

In most methods used today, clinical trials designed to evaluate the safety of a new drug or vaccine employ self-report questionnaires, asking participants how they feel before and after receiving the treatment. A new study from Tel Aviv University enables developers, for the first time in the world, to determine vaccine safety via smart sensors that measure objective physiological parameters. According to the researchers, most clinical trials testing the safety of new vaccines, including COVID-19 vaccines, rely on participants' subjective reports, which can lead to biased results. In contrast, objective physiological data, obtained through sensors attached to the body, is clear and unambiguous.

The study was led by Dr. Yftach Gepner of the Department of Epidemiology and Preventive Medicine at TAU's Sackler Faculty of Medicine, together with Dr. Dan Yamin and Dr. Erez Shmueli from TAU's The Iby and Aladar Fleischman Faculty of Engineering. The paper was published in Communications Medicine, a journal from the Nature portfolio.

The end of an era?

Researchers from Tel Aviv University demonstrated that can be used to test new vaccines. The current study was conducted when many Israelis received their second dose of the COVID-19 vaccine. The researchers equipped volunteers with innovative, FDA-approved sensors developed by the Israeli company Biobeat. Attached to their chests, these sensors measured physiological reactions from one day before to three days after receiving the vaccine.

The innovative sensors monitored 13 physiological parameters, such as: , breathing rate, saturation (blood oxygen levels), heartbeat volume, temperature, cardiac output, and . The surprising results:

  • A significant discrepancy was found between subjective self-reports about side effects and actual measurements. That is, in nearly all objective measures, significant changes were identified after vaccination, even for subjects who reported having no reaction at all.
  • In addition, the study found that side effects escalate over the first 48 hours, and then parameters return to the level measured before vaccination. In other words: a direct assessment of the vaccine's safety identified during the first 48 hours, with levels re-stabilizing afterwards.

"The message from our study is clear," says Dr. Gepner. "In 2022 the time has come to conduct continual, sensitive, objective testing of the safety of new vaccines and therapies. There is no reason to rely on self-reports or wait for the occurrence of rare side effects like myocarditis, an inflammation of the heart muscle, which occurs in one of 10,000 patients. Preliminary signs that predict such conditions can be detected with advanced sensors, identifying normal vs. extreme alterations in physiological parameters and any risk of inflammation. Today, trial participants are invited to the clinic for blood pressure testing, but often their blood pressure rises just because the situation is stressful. Continual monitoring at home solves these problems with simple, convenient, inexpensive, and accurate means. This is the kind of medicine we should strive for in 2022."


Explore further

Study provides more reassuring data on rare heart condition after COVID vaccination

More information: Yftach Gepner et al, Utilizing wearable sensors for continuous and highly-sensitive monitoring of reactions to the BNT162b2 mRNA COVID-19 vaccine, Communications Medicine (2022). DOI: 10.1038/s43856-022-00090-y
Journal information: Nature

Citation: Using smart sensors to ensure vaccine safety (2022, April 13) retrieved 1 July 2022 from https://medicalxpress.com/news/2022-04-smart-sensors-vaccine-safety.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
39 shares

Feedback to editors